Mechanism of Atorvastatin in Treating Hepatocellular Carcinoma: a Study Based on Network Pharmacology, Molecular Docking, and Bioinformatics Analysis

Overview

Journal Naunyn Schmiedebergs Arch Pharmacol

Specialty Pharmacology

Date 2024 Nov 28

PMID 39607545

Authors

Youwen Hu

Yangyang Xiao

Affiliations

Soon will be listed here.

Abstract

Hepatocellular carcinoma (HCC) is a tumor with high morbidity and mortality. Current research suggests that statins may aid in its prevention and treatment, while studies on the associated mechanisms remain limited. Therefore, we aim to reveal the mechanism of atorvastatin treatment for HCC by using network pharmacology and bioinformatics methods. The databases SwissTargetPrediction, PharmMapper, and DrugBank were utilized to obtain targets of atorvastatin, while GSE169289, GSE135631, and GSE207435 were used to identify differentially expressed genes (DEGs) for HCC. The overlap between the two groups was used to identify atorvastatin's target for treating HCC. Following protein-protein interaction (PPI) analysis, hub genes were identified using Cytoscape software and LASSO analysis. The hub genes were further validated using data from The Cancer Genome Atlas (TCGA) and The Human Protein Atlas (HPA) databases. To evaluate the clinical significance of the hub genes, Kaplan-Meier (KM) survival analysis and Cox analysis were conducted. Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Set Enrichment Analysis (GSEA) were performed to investigate potential mechanisms. Finally, molecular docking analysis was performed to validate the interaction between atorvastatin and the hub genes. A total of 1948 DEGs of HCC and 380 targets of atorvastatin were identified, respectively. After taking the intersection, 79 genes were identified as potential targets of atorvastatin for HCC treatment. After multiple screening methods, CYP2C9 was ultimately identified as the hub gene. Analysis of data from TCGA and HPA databases showed reduced expression of CYP2C9 in HCC tissues. KM and Cox analysis showed a favorable prognosis for HCC patients with high CYP2C9 expression. KEGG and GSEA indicated that metabolism of xenobiotics by cytochrome P450, and PPAR signaling pathway could be the potential mechanisms for atorvastatin in treating HCC. Molecular docking analysis revealed that atorvastatin binds to CYP2C9 with a binding energy of - 8.837, indicating highly stable binding. CYP2C9 is associated with the prognosis of HCC patients and could serve as a potential target for atorvastatin treatment in HCC.

References

Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf A . Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013; 39(4):782-95. DOI: 10.1016/j.immuni.2013.10.003. View

Bray F, Laversanne M, Sung H, Ferlay J, Siegel R, Soerjomataram I . Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3):229-263. DOI: 10.3322/caac.21834. View

Chen W, Yu Y, Chen M, Shia B, Wu S . Statin Use During Concurrent Chemoradiotherapy With Improved Survival Outcomes in Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Nationwide Cohort Study. J Thorac Oncol. 2023; 18(8):1082-1093. DOI: 10.1016/j.jtho.2023.04.005. View

Chen X, Wu T, Xian L, Ma L, Li N, Liu W . circGLS2 inhibits hepatocellular carcinoma recurrence via regulating hsa-miR-222-3p-PTEN-AKT signaling. Signal Transduct Target Ther. 2023; 8(1):67. PMC: 9935627. DOI: 10.1038/s41392-022-01275-6. View

Coffin P, He A . Hepatocellular Carcinoma: Past and Present Challenges and Progress in Molecular Classification and Precision Oncology. Int J Mol Sci. 2023; 24(17). PMC: 10487618. DOI: 10.3390/ijms241713274. View

Daina A, Michielin O, Zoete V . SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules. Nucleic Acids Res. 2019; 47(W1):W357-W364. PMC: 6602486. DOI: 10.1093/nar/gkz382. View

Deza Z, Caimi G, Noelia M, Coli L, Ridruejo E, Alvarez L . Atorvastatin shows antitumor effect in hepatocellular carcinoma development by inhibiting angiogenesis via TGF-β1/pERK signaling pathway. Mol Carcinog. 2022; 62(3):398-407. DOI: 10.1002/mc.23494. View

Digre A, Lindskog C . The human protein atlas-Integrated omics for single cell mapping of the human proteome. Protein Sci. 2023; 32(2):e4562. PMC: 9850435. DOI: 10.1002/pro.4562. View

El-Serag H, Johnson M, Hachem C, Morgana R . Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. Gastroenterology. 2009; 136(5):1601-8. PMC: 2677134. DOI: 10.1053/j.gastro.2009.01.053. View

10.

Franz M, Lopes C, Fong D, Kucera M, Cheung M, Siper M . Cytoscape.js 2023 update: a graph theory library for visualization and analysis. Bioinformatics. 2023; 39(1). PMC: 9889963. DOI: 10.1093/bioinformatics/btad031. View

11.

Liu S, Wang J, Liu M, Guo D, Wen Q, Liang Y . ILF2 protein is a promising serum biomarker for early detection of gastric cancer. BMC Cancer. 2024; 24(1):1447. PMC: 11587746. DOI: 10.1186/s12885-024-13205-6. View

12.

Hanahan D . Hallmarks of Cancer: New Dimensions. Cancer Discov. 2022; 12(1):31-46. DOI: 10.1158/2159-8290.CD-21-1059. View

13.

Hanzelmann S, Castelo R, Guinney J . GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013; 14:7. PMC: 3618321. DOI: 10.1186/1471-2105-14-7. View

14.

Ishtiaq S, Arshad M, Khan J . PPARγ signaling in hepatocarcinogenesis: Mechanistic insights for cellular reprogramming and therapeutic implications. Pharmacol Ther. 2022; 240:108298. DOI: 10.1016/j.pharmthera.2022.108298. View

15.

Jeon D, Cha H, Chung S, Choi J, Lee D, Shim J . Association between statin use and the prognosis of hepatocellular carcinoma after resection: a nationwide cohort study. EClinicalMedicine. 2023; 65:102300. PMC: 10641481. DOI: 10.1016/j.eclinm.2023.102300. View

16.

Kanehisa M, Furumichi M, Sato Y, Kawashima M, Ishiguro-Watanabe M . KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 2022; 51(D1):D587-D592. PMC: 9825424. DOI: 10.1093/nar/gkac963. View

17.

Kim S, Chen J, Cheng T, Gindulyte A, He J, He S . PubChem in 2021: new data content and improved web interfaces. Nucleic Acids Res. 2020; 49(D1):D1388-D1395. PMC: 7778930. DOI: 10.1093/nar/gkaa971. View

18.

Lee H, Lee S, Jang J, Bae S, Choi J, Yoon S . Anticancer Effect of Statins in Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma. Liver Transpl. 2021; 28(3):397-406. DOI: 10.1002/lt.26258. View

19.

Li X, Liu L, Hu Y . Statin use and the prognosis of patients with hepatocellular carcinoma: a meta-analysis. Biosci Rep. 2020; 40(4). PMC: 7133516. DOI: 10.1042/BSR20200232. View

20.

Li D, Lin X, Li J, Liu X, Zhang F, Tang W . Eleven metabolism‑related genes composed of Stard5 predict prognosis and contribute to EMT phenotype in HCC. Cancer Cell Int. 2023; 23(1):277. PMC: 10656919. DOI: 10.1186/s12935-023-03097-0. View